Charles River to pay $875M to buy Cognate BioServices

By The Science Advisory Board staff writers

February 17, 2021 -- Charles River Laboratories has signed a deal to pay about $875 million in cash to acquire cell and gene manufacturer Cognate BioServices.

Cognate offers comprehensive manufacturing solutions for cell therapies, as well as for production of plasmid DNA. The company provides its customers with cell and gene therapy development, testing, and manufacturing services. Cognate offers integrated solutions for the entire drug development lifecycle from basic research and discovery through current good manufacturing practice (cGMP) production.

The transaction is expected to close by the end of the first quarter of 2021. The acquisition of the Memphis, TN-based manufacturer will establish Charles River as a partner for cell and gene therapy contract development and manufacturing organization (CDMO) platforms.

Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles...
Charles River Laboratories acquires Distributed Bio
Charles River Laboratories has acquired Silicon Valley-based antibody drug discovery firm Distributed Bio for $83 million in cash.
BioVaxys' COVID-19 vaccine may provide longer protection
BioVaxys Technology has released data about its haptenized viral protein vaccine technology used in BVX-0320, its COVID-19 vaccine candidate. The candidate...
Charles River, Deciphex form digital pathology partnership
Charles River Laboratories has entered into a partnership with software firm Deciphex to offer a digital pathology workflow platform.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter